The Department of Health and Human Services Centers for Disease Control and Prevention awarded a $248,857.00 Firm Fixed Price purchase order to Genscript USA Inc., a biotechnology company, for the provision of "FAST GENE SYNTHESIS" services. The contract has an August 7, 2023 completion date and was awarded on August 8, 2022. Genscript is a for-profit organization that provides gene synthesis, gene editing, custom protein and antibody production, and other molecular biology services to...
This federal contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention (HHS/CDC) to Genscript USA Inc., a for-profit biotechnology company, provides gene synthesis services. The $245,750.00 firm-fixed-price purchase order has a completion date of September 29, 2021 and was awarded on August 18, 2020. The contract does not have a set-aside designation. Genscript is a provider of gene synthesis, gene editing, custom protein and antibody...
This federal contract award to Genscript USA Inc., a biotechnology company based in New Jersey, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS). The $4,196.16 firm fixed-price purchase order is for gene synthesis services. Genscript, a for-profit organization, has a history of providing a wide range of molecular biology products and services to...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $19,316.68 firm fixed price purchase order to Genscript USA Inc., a for-profit biotechnology company based in Piscataway, New Jersey. The contract is for the provision of custom plasmid preparation services to support biomedical research and public health initiatives. Genscript has extensive experience providing specialized products and services to federal...
This firm fixed-price purchase order, valued at $14,607.70, was awarded by the National Institute of Child Health and Human Development (NICHD) to Genscript USA Inc. for gene synthesis and cloning services. The ultimate completion date is August 29, 2024. Genscript is a biotechnology company based in Piscataway, New Jersey that specializes in molecular biology products and services to support biomedical research and public health initiatives for various federal agencies, including the National...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm fixed price purchase order to Genscript USA Inc., a for-profit biotechnology company, for plasmid cloning and propagation services. The $11,409.96 contract is for work to be performed in Piscataway, New Jersey. Genscript, which specializes in gene synthesis, gene editing, and other molecular biology services, has received numerous prime and...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a firm fixed-price purchase order to Genscript USA Inc., a for-profit biotechnology company, for the development of murine hybridoma and V region sequencing, custom design chimeric plasmid, and custom proteins. The $249,785.00 contract has a completion date of September 29, 2022 and was awarded on September 30, 2021. Genscript is a provider of gene synthesis, gene editing, custom protein and antibody...
This federal contract award to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey, is for the provision of a wide range of molecular biology products and services to support biomedical research and public health initiatives. The $19,395.39 firm fixed-price purchase order contract, awarded by the National Institute of Child Health and Human Development (NICHD), covers gene synthesis, cloning, protein expression and purification, antibody production, and other...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a firm-fixed-price purchase order contract to Genscript USA Inc., a for-profit biotechnology company, for stable cell line development services with a completion date of April 1, 2020. The contract had a potential value of $130,400.99 and was not set aside for any particular business type. Genscript provides a range of molecular biology products and services, including gene synthesis, gene editing,...
This contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Cancer Institute to Genscript USA Inc., a for-profit biotechnology company based in Piscataway, New Jersey. The $3,182.40 firm fixed price delivery order is for gene synthesis services. Genscript specializes in providing customized DNA, antibodies, proteins, peptides, and other molecular biology products and services to support biomedical research and public health initiatives...